Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Gynecologic 1

Conditions

Colorectal Neoplasms 2679Pancreatic Neoplasms 1470Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1129Rectal Neoplasms 980Esophageal Neoplasms 728Neoplasms 559Liver Neoplasms 533Breast Neoplasms 473Neoplasm Metastasis 373Lung Neoplasms 325Carcinoma, Non-Small-Cell Lung 292Gastrointestinal Neoplasms 277Ovarian Neoplasms 258Prostatic Neoplasms 229Cholangiocarcinoma 221Head and Neck Neoplasms 180Gastrointestinal Stromal Tumors 176Melanoma 165Esophageal Squamous Cell Carcinoma 164Barrett Esophagus 156Uterine Cervical Neoplasms 151Biliary Tract Neoplasms 149Adenocarcinoma Of Esophagus 148Gallbladder Neoplasms 136Carcinoma, Renal Cell 134Urinary Bladder Neoplasms 132Sarcoma 131Anus Neoplasms 124

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Paresthesia × Gastrointestinal × Clear all
NCT01775449 2017-07-11

NEUROXAPOL

University Hospital, Clermont-Ferrand

Phase 3 Completed
80 enrolled
Gastrointestinal

Digestive System Neoplasms, Hyperalgesia, Paresthesia

NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00272051 2006-09-13

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Sanofi

Phase 3 Completed
620 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡